You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMedroxyprogesterone Acetate
Accession NumberDB00603  (APRD00627)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications.
MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. [Wikipedia]

Structure
Thumb
Synonyms
SynonymLanguageCode
(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dioneNot AvailableNot Available
17-Acetoxy-6alpha-methylprogesteroneNot AvailableNot Available
17-Acetoxy-6α-methylprogesteroneNot AvailableNot Available
17alpha-Hydroxy-6alpha-methylprogesterone acetateNot AvailableNot Available
17α-hydroxy-6α-methylprogesterone acetateNot AvailableNot Available
6-alpha-Methyl-17-alpha-acetoxyprogesteroneNot AvailableNot Available
6-alpha-Methyl-17-alpha-hydroxyprogesterone acetateNot AvailableNot Available
6alpha-Methyl-17-acetoxy progesteroneNot AvailableNot Available
6alpha-Methyl-17alpha-hydroxyprogesterone acetateNot AvailableNot Available
6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetateNot AvailableNot Available
6α-Methyl-17-acetoxy progesteroneNot AvailableNot Available
6α-Methyl-17α-hydroxyprogesterone acetateNot AvailableNot Available
Medroxyacetate progesteroneNot AvailableNot Available
Medroxyprogesterone 17-acetateNot AvailableNot Available
Medroxyprogesterone acetateNot AvailableNot Available
MethylacetoxyprogesteroneNot AvailableNot Available
MetigestronaNot AvailableNot Available
MPANot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Proveratablet10 mgoralPharmacia and Upjohn Company1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Proveratablet2.5 mgoralPharmacia and Upjohn Company1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Proveratablet5 mgoralPharmacia and Upjohn Company1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-proverainjection, suspension400 mg/mLintramuscularPharmacia and Upjohn Company1960-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-proverainjection, suspension150 mg/mLintramuscularPharmacia and Upjohn Company1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-subq Proverainjection, suspension104 mg/.65mLsubcutaneousPharmacia and Upjohn Company2005-05-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-proverainjection, suspension150 mg/mLintramuscularPharmacia and Upjohn Company1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralPd Rx Pharmaceuticals, Inc.1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralREMEDYREPACK INC.2014-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralREMEDYREPACK INC.2011-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularREMEDYREPACK INC.2013-05-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularREMEDYREPACK INC.2014-12-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-proverainjection, suspension150 mg/mLintramuscularA S Medication Solutions Llc1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-proverainjection, suspension150 mg/mLintramuscularA S Medication Solutions Llc1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularA S Medication Solutions Llc1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralPhysicians Total Care, Inc.1994-07-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralPhysicians Total Care, Inc.1995-04-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralPhysicians Total Care, Inc.1995-09-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depo-proverainjection, suspension400 mg/mLintramuscularPhysicians Total Care, Inc.1995-01-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularPhysicians Total Care, Inc.2005-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralCardinal Health1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralPd Rx Pharmaceuticals, Inc.1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralGreenstone LLC1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralGreenstone LLC1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralGreenstone LLC1959-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularGreenstone LLC1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularGreenstone LLC1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Makenainjection250 mg/mLintramuscularLumara Health Inc.2011-02-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralAmerican Health Packaging2012-01-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularPreferred Pharmaceuticals, Inc1992-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Medroxyprogesterone Acetatetablet10 mgoralBarr Laboratories Inc.1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralBarr Laboratories Inc.1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralBarr Laboratories Inc.1996-12-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetateinjection150 mg/mLintramuscularTeva Parenteral Medicines, Inc2004-09-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralBlenheim Pharmacal, Inc.2010-05-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralRebel Distributors Corp.1996-08-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralAidarex Pharmaceuticals LLC1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralAidarex Pharmaceuticals LLC1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralAidarex Pharmaceuticals LLC1996-12-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralREMEDYREPACK INC.2013-05-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralREMEDYREPACK INC.2014-01-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralA S Medication Solutions Llc1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralA S Medication Solutions Llc1996-12-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralPd Rx Pharmaceuticals, Inc.2011-01-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralbryant ranch prepack1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralbryant ranch prepack1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralbryant ranch prepack1996-12-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralReady Meds1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet2.5 mgoralReady Meds1996-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet5 mgoralDispensing Solutions, Inc.2011-01-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Medroxyprogesterone Acetatetablet10 mgoralPreferred Pharmaceuticals, Inc2012-02-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
Depo-subq provera 104Not Available
Brand mixtures
Brand NameIngredients
LunelleMedroxyprogesterone acetate + Estradiol
SaltsNot Available
Categories
CAS number71-58-9
WeightAverage: 386.5244
Monoisotopic: 386.245709576
Chemical FormulaC24H34O4
InChI KeyPSGAAPLEWMOORI-PEINSRQWSA-N
InChI
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
IUPAC Name
(1S,2R,8S,10R,11S,14R,15S)-14-acetyl-2,8,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl acetate
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Alpha-acyloxy ketone
  • Acetate salt
  • Cyclic ketone
  • Ketone
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
PharmacodynamicsMedroxyprogesterone acetate is a synthetic progestin more potent than progesterone.
Mechanism of actionProgestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
AbsorptionRapidly absorbed from GI tract
Volume of distributionNot Available
Protein binding90%
Metabolism

Hepatic

SubstrateEnzymesProduct
Medroxyprogesterone Acetate
6β-HydroxymedroxyprogesteroneDetails
Medroxyprogesterone Acetate
2β-HydroxymedroxyprogesteroneDetails
Medroxyprogesterone Acetate
1β-HydroxymedroxyprogesteroneDetails
Route of eliminationFollowing oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.
Half life50 days
Clearance
  • 64110 +/- 42662 mL/min [postmenopausal women under fasting conditions with a single Dose of 2 × 10 mg]
  • 74123 +/- 35126 mL/min [postmenopausal women under fasting conditions with a single Dose of 8 × 2.5 mg]
  • 41963 +/- 38402 mL/min [postmenopausal women following daily administration of one PROVERA 10 mg tablet for 7 days]
ToxicitySide effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9617
Caco-2 permeable+0.651
P-glycoprotein substrateSubstrate0.6107
P-glycoprotein inhibitor IInhibitor0.9149
P-glycoprotein inhibitor IIInhibitor0.7016
Renal organic cation transporterNon-inhibitor0.7753
CYP450 2C9 substrateNon-substrate0.8642
CYP450 2D6 substrateNon-substrate0.908
CYP450 3A4 substrateSubstrate0.7744
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 substrateNon-inhibitor0.8907
CYP450 2D6 substrateNon-inhibitor0.9532
CYP450 2C19 substrateNon-inhibitor0.9025
CYP450 3A4 substrateNon-inhibitor0.8095
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.899
Ames testNon AMES toxic0.9775
CarcinogenicityNon-carcinogens0.9273
BiodegradationNot ready biodegradable0.9354
Rat acute toxicity1.8121 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9429
hERG inhibition (predictor II)Non-inhibitor0.7761
Pharmacoeconomics
Manufacturers
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Usl pharma inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular150 mg/mL
Injectionintramuscular250 mg/mL
Injection, suspensionintramuscular150 mg/mL
Injection, suspensionintramuscular400 mg/mL
Injection, suspensionsubcutaneous104 mg/.65mL
Tabletoral10 mg
Tabletoral2.5 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Depo-Provera 400 mg/ml Suspension 2.5ml Vial201.13USD vial
Depo-subq provera 104 syringe108.17USD syringe
Depo-provera 400 mg/ml vial96.7USD ml
Depo-Provera 150 mg/ml Suspension 1ml Syringe94.58USD syringe
MedroxyPROGESTERone Acetate 150 mg/ml Suspension 1ml Syringe60.56USD syringe
MedroxyPROGESTERone Acetate 150 mg/ml Suspension 1ml Vial55.17USD vial
Depo-Provera 150 mg/ml31.02USD ml
Medroxyprogesterone Acetate 150 mg/ml23.05USD ml
Medroxyprogesterone ace powder18.97USD g
Depo-Provera 50 mg/ml6.01USD ml
Provera 10 mg tablet2.03USD tablet
Provera 5 mg tablet1.57USD tablet
Provera 100 mg Tablet1.41USD tablet
Provera 2.5 mg tablet1.15USD tablet
Apo-Medroxy 100 mg Tablet0.96USD tablet
Provera 10 mg Tablet0.73USD tablet
MedroxyPROGESTERone Acetate 10 mg tablet0.51USD tablet
MedroxyPROGESTERone Acetate 5 mg tablet0.48USD tablet
MedroxyPROGESTERone Acetate 2.5 mg tablet0.43USD tablet
Medroxyprogesterone 10 mg tablet0.4USD tablet
Provera 5 mg Tablet0.36USD tablet
Medroxyprogesterone 5 mg tablet0.33USD tablet
Apo-Medroxy 10 mg Tablet0.33USD tablet
Novo-Medrone 10 mg Tablet0.33USD tablet
Medroxyprogesterone 2.5 mg tablet0.32USD tablet
Provera 2.5 mg Tablet0.18USD tablet
Apo-Medroxy 5 mg Tablet0.16USD tablet
Novo-Medrone 5 mg Tablet0.16USD tablet
Apo-Medroxy 2.5 mg Tablet0.08USD tablet
Novo-Medrone 2.5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada24090592006-04-182021-04-25
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point214.5 °CPhysProp
water solubility22.2mg/LNot Available
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00221 mg/mLALOGPS
logP3.42ALOGPS
logP4.13ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)17.82ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity107.81 m3·mol-1ChemAxon
Polarizability44.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra1D NMR
References
Synthesis Reference

Klaus ANNEN, Thomas Linz, Karl-Heinz Neff, Rolf Bohlmann, Henry Laurent, “PROCESS FOR PREPARING 17ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE AND MEGESTROL ACETATE.” U.S. Patent US20090012321, issued January 08, 2009.

US20090012321
General Reference
  1. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH: Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. Pubmed
  2. Lenco W, Mcknight M, Macdonald AS: Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits. Ann Surg. 1975 Jan;181(1):67-73. Pubmed
External Links
ATC CodesNot Available
AHFS Codes
  • 68:32.00
PDB EntriesNot Available
FDA labelDownload (1.2 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
AcenocoumarolProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
AcetohexamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AcitretinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
AlogliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AminoglutethimideMay increase the metabolism of Progestins.
AprepitantMay decrease the serum concentration of Contraceptives (Progestins).
AripiprazoleCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
ArtemetherMay decrease the serum concentration of Contraceptives (Progestins).
AtazanavirMay increase the serum concentration of Contraceptives (Progestins).
BoceprevirMay increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone.
BosentanMay decrease the serum concentration of Contraceptives (Progestins).
ButabarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
ButethalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
CanagliflozinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CarbamazepineMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
ChlorpropamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Citric AcidProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
ClobazamMay decrease the serum concentration of Contraceptives (Progestins).
ColesevelamMay decrease the serum concentration of Contraceptives (Progestins).
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DalteparinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
DarunavirMay decrease the serum concentration of Contraceptives (Progestins).
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DicoumarolProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
Edetic AcidProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
EfavirenzMay decrease the serum concentration of Contraceptives (Progestins).
EnoxaparinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
Ethyl biscoumacetateProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
FelbamateMay decrease the serum concentration of Contraceptives (Progestins).
Fondaparinux sodiumProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
FosamprenavirContraceptives (Progestins) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Contraceptives (Progestins).
FosaprepitantMay decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect.
FosphenytoinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
GliclazideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlimepirideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GliquidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlyburideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GriseofulvinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
HeparinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
HeptabarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
HexobarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
HydrocodoneCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
Insulin AspartHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin DetemirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlargineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlulisineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin LisproHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin RegularHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin, isophaneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LamotrigineMay decrease the serum concentration of Contraceptives (Progestins).
LinagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LopinavirMay decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).
MetforminHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MethohexitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
MetreleptinMay decrease the serum concentration of Contraceptives (Progestins). Metreleptin may increase the serum concentration of Contraceptives (Progestins).
MifepristoneMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
NelfinavirMay decrease the serum concentration of Contraceptives (Progestins).
NevirapineMay decrease the serum concentration of Contraceptives (Progestins).
OxcarbazepineMay decrease the serum concentration of Contraceptives (Progestins).
PentobarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
PerampanelMay decrease the serum concentration of Contraceptives (Progestins).
PhenindioneProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
PhenprocoumonProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
PhenytoinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
PrimidoneMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
prucaloprideMay decrease the serum concentration of Contraceptives (Progestins).
RepaglinideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SaquinavirMay decrease the serum concentration of Contraceptives (Progestins).
SaxagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SecobarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
SelegilineContraceptives (Progestins) may increase the serum concentration of Selegiline.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SugammadexMay decrease the serum concentration of Contraceptives (Progestins).
SulodexideProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
TelaprevirMay decrease the serum concentration of Contraceptives (Progestins).
ThalidomideContraceptives (Progestins) may enhance the thrombogenic effect of Thalidomide.
TipranavirMay increase the serum concentration of Contraceptives (Progestins).
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TolbutamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TopiramateMay decrease the serum concentration of Contraceptives (Progestins).
Tranexamic AcidContraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.
TreprostinilProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
UlipristalMay diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.
VildagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
VoriconazoleMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
WarfarinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
Food Interactions
  • Take with food.

Targets

1. Progesterone receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Progesterone receptor P06401 Details

References:

  1. Risch HA, Bale AE, Beck PA, Zheng W: PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41. Pubmed
  2. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. Pubmed
  3. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. Pubmed
  4. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. Pubmed
  5. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Estrogen receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Estrogen receptor P03372 Details

References:

  1. Jain JK, Li A, Yang W, Minoo P, Felix JC: Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril. 2007 Jan;87(1):8-23. Epub 2006 Nov 7. Pubmed
  2. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. Pubmed
  3. Lessey BA, Palomino WA, Apparao K, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006 Oct 9;4 Suppl 1:S9. Pubmed
  4. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. Pubmed
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Zhang JW, Liu Y, Zhao JY, Wang LM, Ge GB, Gao Y, Li W, Liu HT, Liu HX, Zhang YY, Sun J, Yang L: Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8. Epub 2008 Aug 25. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 P26439 Details

References:

  1. Lee TC, Miller WL, Auchus RJ: Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab. 1999 Jun;84(6):2104-10. Pubmed

4. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11